AMPH Q4 2024 Earnings — Amphastar Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

AMPHAmphastar Pharmaceuticals, Inc.

$894M

Q4 2024 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$187M+4.7% YoY

Gross Profit

$87M46.5% margin

Operating Income

$45M24.2% margin

Net Income

$38M20.4% margin

EPS (Diluted)

$0.74

QoQ Revenue Growth

-1.2%

Cash Flow

Operating Cash Flow

$29M

Free Cash Flow

$17M

Stock-Based Comp.

$6M

Balance Sheet

Total Assets

$1.6B

Total Liabilities

$845M

Stockholders' Equity

$732M

Cash & Equivalents

$152M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$187M	$178M	+4.7%
Gross Profit	$87M	$96M	-9.9%
Operating Income	$45M	$54M	-16.4%
Net Income	$38M	$36M	+5.0%

Revenue Segments

Product

$524M100%

Geographic Segments

UNITED STATES

$175M94%

FRANCE

$9M5%

CHINA

$2M1%